Literature DB >> 12244092

Structural basis for Chk1 inhibition by UCN-01.

Baoguang Zhao1, Michael J Bower, Patrick J McDevitt, Huizhen Zhao, Stephen T Davis, Kyung O Johanson, Susan M Green, Nestor O Concha, Bin-Bing S Zhou.   

Abstract

Chk1 is a serine-threonine kinase that plays an important role in the DNA damage response, including G(2)/M cell cycle control. UCN-01 (7-hydroxystaurosporine), currently in clinical trials, has recently been shown to be a potent Chk1 inhibitor that abrogates the G(2)/M checkpoint induced by DNA-damaging agents. To understand the structural basis of Chk1 inhibition by UCN-01, we determined the crystal structure of the Chk1 kinase domain in complex with UCN-01. Chk1 structures with staurosporine and its analog SB-218078 were also determined. All three compounds bind in the ATP-binding pocket of Chk1, producing only slight changes in the protein conformation. Selectivity of UCN-01 toward Chk1 over cyclin-dependent kinases can be explained by the presence of a hydroxyl group in the lactam moiety interacting with the ATP-binding pocket. Hydrophobic interactions and hydrogen-bonding interactions were observed in the structures between UCN-01 and the Chk1 kinase domain. The high structural complementarity of these interactions is consistent with the potency and selectivity of UCN-01.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12244092     DOI: 10.1074/jbc.M201233200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  45 in total

1.  Discovery of novel checkpoint kinase 1 inhibitors by virtual screening based on multiple crystal structures.

Authors:  Yan Li; Dong Joon Kim; Weiya Ma; Ronald A Lubet; Ann M Bode; Zigang Dong
Journal:  J Chem Inf Model       Date:  2011-10-12       Impact factor: 4.956

2.  p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage.

Authors:  H Christian Reinhardt; Aaron S Aslanian; Jacqueline A Lees; Michael B Yaffe
Journal:  Cancer Cell       Date:  2007-02       Impact factor: 31.743

3.  Reconstitution of modular PDK1 functions on trans-splicing of the regulatory PH and catalytic kinase domains.

Authors:  Hassan Al-Ali; Timothy J Ragan; Xinxin Gao; Thomas K Harris
Journal:  Bioconjug Chem       Date:  2007-05-15       Impact factor: 4.774

4.  Further Characterization of Calcineurin B-Like Protein and Its Interacting Partner CBL-Interacting Protein Kinase from Pisum sativum.

Authors:  Narendra Tuteja; Shilpi Mahajan
Journal:  Plant Signal Behav       Date:  2007-09

5.  Transferable scoring function based on semiempirical quantum mechanical PM6-DH2 method: CDK2 with 15 structurally diverse inhibitors.

Authors:  Petr Dobeš; Jindřich Fanfrlík; Jan Rezáč; Michal Otyepka; Pavel Hobza
Journal:  J Comput Aided Mol Des       Date:  2011-02-01       Impact factor: 3.686

6.  Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors.

Authors:  Edward Sausville; Patricia Lorusso; Michael Carducci; Judith Carter; Mary F Quinn; Lisa Malburg; Nilofer Azad; David Cosgrove; Richard Knight; Peter Barker; Sonya Zabludoff; Felix Agbo; Patricia Oakes; Adrian Senderowicz
Journal:  Cancer Chemother Pharmacol       Date:  2014-01-22       Impact factor: 3.333

7.  Crystal structure of domain-swapped STE20 OSR1 kinase domain.

Authors:  Seung-Jae Lee; Melanie H Cobb; Elizabeth J Goldsmith
Journal:  Protein Sci       Date:  2009-02       Impact factor: 6.725

Review 8.  Clinically Applicable Inhibitors Impacting Genome Stability.

Authors:  Anu Prakash; Juan F Garcia-Moreno; James A L Brown; Emer Bourke
Journal:  Molecules       Date:  2018-05-13       Impact factor: 4.411

9.  On the origins of enzyme inhibitor selectivity and promiscuity: a case study of protein kinase binding to staurosporine.

Authors:  Duangrudee Tanramluk; Adrian Schreyer; William R Pitt; Tom L Blundell
Journal:  Chem Biol Drug Des       Date:  2009-07       Impact factor: 2.817

Review 10.  Marine pyrrolocarbazoles and analogues: synthesis and kinase inhibition.

Authors:  Sébastien Deslandes; Stefan Chassaing; Evelyne Delfourne
Journal:  Mar Drugs       Date:  2009-12-01       Impact factor: 5.118

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.